Generic Amaryl is sold under the name Glimepiride tablets. Interestingly, generic Amaryl is available in more strengths than the brand-name Amaryl. Brand-name Amaryl is available in only three strengths (1, 2, and 4 mg), while generic Amaryl is available in the following strengths:
* Glimepiride 1 mg tablets
* Glimepiride 2 mg tablets
* Glimepiride 3 mg tablets
* Glimepiride 4 mg tablets
* Glimepiride 6 mg tablets
* Glimepiride 8 mg tablets.
There is no fixed dosage regimen for the management of diabetes mellitus with AMARYL or any other hypoglycemic agent. The patient’s1c must be measured periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e., loss of adequate blood glucose lowering response after an initial period of effectiveness. Glycosylated hemoglobin levels should be performed to monitor the patient’s response to therapy.
Short-term administration of AMARYL may be sufficient during periods of transient loss of control in patients usually controlled well on diet and exercise.
The usual starting dose of AMARYL as initial therapy is 1-2 mg once daily, administered with breakfast or the first main meal. Those patients who may be more sensitive to hypoglycemic drugs should be started at 1 mg once daily, and should be titrated carefully. (See PRECAUTIONS Section for patients at increased risk.)
No exact dosage relationship exists between AMARYL and the other oral hypoglycemic agents. The maximum starting dose of AMARYL should be no more than 2 mg.
Failure to follow an appropriate dosage regimen may precipitate hypoglycemia. Patients who do not adhere to their prescribed dietary and drug regimen are more prone to exhibit unsatisfactory response to therapy.
The usual maintenance dose is 1 to 4 mg once daily. The maximum recommended dose is 8 mg once daily. After reaching a dose of 2 mg, dosage increases should be made in increments of no more than 2 mg at 1-2 week intervals based upon the patient’s term efficacy should be monitored by measurement of HbA1c levels, for example, every 3 to 6 months.
AMARYL-Metformin Combination Therapy
If patients do not respond adequately to the maximal dose of AMARYL monotherapy, addition of metformin may be considered. Published clinical information exists for the use of other sulfonylureas including glyburide, glipizide, chlorpropamide, and tolbutamide in combination with metformin.
With concomitant AMARYL and metformin therapy, the desired control of blood glucose may be obtained by adjusting the dose of each drug. However, attempts should be made to identify the minimum effective dose of each drug to achieve this goal. With concomitant AMARYL and metformin therapy, the risk of hypoglycemia associated with AMARYL therapy continues and may be increased. Appropriate precautions should be taken.
Combination therapy with AMARYL and insulin may also be used in secondary failure patients. The fasting glucose level for instituting combination therapy is in the range of > 150 mg/dL in plasma or serum depending on the patient. The recommended AMARYL dose is 8 mg once daily administered with the first main meal. After starting with low-dose insulin, upward adjustments of insulin can be done approximately weekly as guided by frequent measurements of fasting blood glucose. Once stable, combination-therapy patients should monitor their capillary blood glucose on an ongoing basis, preferably daily. Periodic adjustments of insulin may also be necessary during maintenance as guided by glucose and HbA1c levels.
AMARYL (glimepiride tablets) is not recommended for use in pregnancy or nursing mothers. Data are insufficient to recommend pediatric use of AMARYL. In elderly, debilitated, or malnourished patients, or in patients with renal or hepatic insufficiency, the initial dosing, dose increments, and maintenance dosage should be conservative to avoid hypoglycemic reactions. (See CLINICAL PHARMACOLOGY, Special Populations and PRECAUTIONS, General.)
As with other sulfonylurea hypoglycemic agents, no transition period is necessary when transferring patients to AMARYL. Patients should be observed carefully (1-2 weeks) for hypoglycemia when being transferred from longer half-life sulfonylureas (e.g., chlorpropamide) to AMARYL due to potential overlapping of drug effect.
The answer to how bad junk food is for you depends on how much of it you eat.
According to the experts we consulted in making What’s Really In Our Food?, having a burger or pizza now and again as part of a properly balanced diet that includes plenty of vitamins and nutrients is not going to damage your health.
Instead, most of the experts agreed that the real problem lies with what they call “junk diets”. This is when people eat junk food to the exclusion of everything else.
Having a sugary breakfast, a burger for lunch and a pizza for dinner every day – and no fruit and vegetables – is the kind of diet that over the long term can lead to serious health problems including Type II diabetes, heart attack and stroke.
Almost one in five children under-15 are currently obese, and if current trends continue, more than half of the adult population could be clinically obese by 2050.
To help us make more informed decisions about what we eat dieticians sometimes refer to what are called “Guideline Daily Amounts” or GDAs for short.
These are daily targets to aim at in order that we do not eat the quantities of food that can lead to health problems.
Guideline daily amounts for men, women and children
Using this scale it is possible to assess how some types of fast foods can contribute a huge number of calories, salt, fat or sugar in a single portion.
For example, a Burger King double whopper with cheese contains 923 calories. That is almost half what a woman should eat in an entire day.
A muffin from a high street coffee chain can contain 500 calories. This is a fifth of a man’s guideline daily amount in one snack.
Equally a single slice of Domino’s double decadence cheese and tomato pizza can contain 1.9g of salt, or about a third of the guideline daily amount for both men and women.
With this in mind, the recommendations of the experts we talked to was that we should view junk food as a treat and not a staple.
We should be careful about not eating it too much or too often and try to eat small portions.
And we should also try to eat lots of fruit and vegetables. This is something many fast food companies have already taken on board and are trying to offer a greater range of products.
So if you love junk food – do not worry – you do not have to give it up.
What’s Really In Our Food? was broadcast from Monday 26 to Friday 30 November 2007 at 0915 GMT on BBC One.
from Diabetes Care Results A total of 83 patients were randomized to the two treatment arms. Of those, 2 patients were excluded from the ITT analysis for HbA1c (acarbose n = 38, placebo n = 43) and 1 patient had no baseline fasting blood glucose data and was thus excluded from the ITT analysis for FBG (acarbose n = 39, placebo n = 43). In the PP population, 71 patients were included for HbA1c analysis (acarbose n = 33, placebo n = 38) and 74 for FBG analysis (acarbose n = 35, placebo n = 39). All randomized patients were included in the safety analysis (acarbose n = 40, placebo n = 43). Baseline demographic data and efficacy variables of all randomized subjects compared well between the treatment groups (Table 1). Both treatment groups received the same median dosage of metformin (1,700 mg/day). Figure 1A shows the change in mean HbA1c levels during the study course (ITT analysis). Significant differences between the treatment groups compared to baseline were seen for weeks 12 and 24 (P = 0.0009 and P = 0.0023, respectively). Mean HbA1c levels increased in the placebo group from 7.82 ± 0.83% at baseline to 8.1 ± 1.06% at week 12 and 8.5 ± 1.44% at study end. The mean increase after 24 weeks was 0.68 ± 1.17%, with a significant overall time effect (P = 0.0001). In the acarbose group, levels decreased from 8.02 ± 0.85% at baseline to 7.78 ± 1.0% at week 12 (P = 0.0261). Levels then increased to 7.97 ± 1.1% at study end (mean change after 24 weeks was -0.05 ± 0.8%). There was no significant overall time effect for acarbose. The adjusted least square means for the change in HbA1c from baseline to week 24 showed a reduction of 0.16 ± 0.18% in the acarbose arm compared to an increase of 0.86 ± 0.16% in the placebo group, with a statistically significant difference between the treatment arms of 1.02% (95% CI 0.543-1.497, P = 0.0001). There was a significantly greater proportion of responders in the acarbose group (n = 18; 47%) than in the placebo group (n = 6; 14%) (P = 0.001) at the end of the study. Figure 1. (click image to zoom) Change in mean HbA1c (A) and mean FBG (B) during a 24-week treatment period with acarbose (•) or placebo () adjunctive therapy in the ITT population. Mean levels of the secondary efficacy variable FBG increased in the placebo arm from baseline (9.41 ± 1.99 mmol/l) to week 4 (10.06 ± 2.43 mmol/l) and continued to increase to the end of study (10.77 ± 3.39 mmol/l), whereas levels in the acarbose arm varied only slightly from baseline (Fig. 1B). The mean increase was 1.36 ± 2.88 mmol/l for the placebo and 0.08 ± 1.98 mmol/l for the acarbose group. The adjusted least square means showed an increase at end point in both groups: 0.34 ± 0.42 mmol/l for acarbose compared to 1.48 ± 0.39 mmol/l for placebo patients, with a statistically significant difference of 1.132 mmol/l between the two groups (95% CI 0.056-2.208, P = 0.0395). PP analyses for both variables showed similar results, but were not statistically significant for treatment differences concerning FBG. Of the 83 patients valid for safety analysis, 76 completed the study. Mean study duration was 169 days for both acarbose (29-184 days) and placebo (39-176 days). Overall compliance (80-120% compliance) was 100% for acarbose and 95.3% for placebo patients. In all, five patients reduced the medication dose to 50 mg b.i.d. because of adverse events (acarbose, n = 3; placebo, n = 2); three of these patients later reverted back to the original dosage. Patients in both treatment groups experienced a small mean weight reduction over the study period (1.32 ± 2.37 kg for acarbose vs. 0.43 ± 2.9 kg for placebo patients), which was not significantly different (P = 0.13). There were also no significant changes in vital signs. Changes in routine laboratory parameters were similar in both treatment groups, except for one patient (acarbose group) with elevated liver function enzymes who was withdrawn from the study. In total, seven patients were prematurely withdrawn from the study during the 24-week treatment period: four because of treatment-emergent adverse events, one patient on placebo because of constipation and depression, and three patients on acarbose with flatulence, flatulence accompanied by abdominal pain, and the aforementioned elevated liver enzymes. A serious adverse event with remote or no relation to the study medication was experienced by two acarbose patients and one placebo patient; no fatalities occurred. Treatment-emergent adverse events with a relation to the study medication rated as “possible” or “probable” were reported by 75% of acarbose and 55.8% of placebo patients. The main difference between the treatment groups was the higher frequency of gastrointestinal complaints in the acarbose group (Table 2).
from Drug Benefit Trends
What’s Ahead
While the ADA and other organizations fight — unsuccessfully, for now — for additional federal funding for research, studies of ways to stop or slow the devastating effects of diabetes continue. The AAHP and the ADA have joined forces in a national effort, “Taking on Diabetes.” The goal is to promote successful diabetes care by advancing effective clinical practices, developing worksite health programs and community partnerships, and providing annual education programs. As of May, 335 health plans had pledged to participate. Diabetes programs are slowly shifting from targeting only the sickest patients — or those having the most difficulty managing the disease — to more comprehensive efforts that provide additional care and support to every patient with diabetes within a particular health plan, employer group, or community.
Conception and Text editionConstruct
Goal: Liraglutide is a long-acting glucagon-like peptide 1 analog designed for once daily intromission.
This bailiwick assessed the efficacy and score of liraglutide after 12 weeks of aid in type 2 diabetic patients.
Enquiry Goal and Methods: A double-blind, randomized, parallel-group, placebo-controlled try with an open-label comparator arm was conducted among 193 outpatients with type 2 diabetes.
The mean age was 56.6 long time and the mean HbA1c was 7.6% across the idiom groups.
Patients were randomly assigned to one of five fixed-dosage groups of liraglutide (0.045, 0.225, 0.45, 0.60, or 0.75 mg), vesper, or open-label sulfonylurea (glimepiride, 1-4 mg).
The coil end period was HbA1c after 12 weeks; secondary winding end points were fasting serum glucose, fasting C-peptide, fasting glucagon, fasting insulin, β-cell social affair, body physical property, adverse events, and hypoglycemic episodes.
Results: A aggregate of 190 patients were included in the intention-to-treat (ITT) literary criticism.
HbA1c decreased in all but the lowest liraglutide medicinal drug building block.
In the 0.75-mg liraglutide building block, HbA1c decreased by 0.75 percent points (P < 0.0001) and fasting glucose decreased by 1.8 mmol/l (P = 0.0003) compared with medicinal drug.
Transmutation in glycemic bodily function was evident after 1 week.
Body weighting decreased by 1.2 kg in the 0.45-mg liraglutide grouping (P = 0.0184) compared with medicinal drug.
The proinsulin-to-insulin quantitative relation decreased in the 0.75-mg liraglutide abstract entity (-0.18; P = 0.0244) compared with medication.
Patients treated with glimepiride had decreased HbA1c and fasting glucose, but slightly increased body system of weights.
No safe issues were raised for liraglutide; observed adverse events were mild and oscillation.
Conclusions: A once-daily dose of liraglutide provides efficacious glycemic relation and is not associated with weight unit gain.
Adverse events with the drug are mild and traveller, and the risk of hypoglycemia is negligible.Institution
Type 2 diabetes is characterized by insulin resistor and defective β-cell computer software and is associated with hyperglucagonemia, increased hepatic glucose display, and obesity. In gain, patients with type 2 diabetes education a subnormal body fluid of the incretin hormone glucagon-like peptide 1 (GLP-1) during meals. Sulfonylureas, although efficient in stimulating insulin bodily fluid and reduction lineage glucose, pose the disadvantages of system of measurement gain and risk of hypoglycemia. Studies have demonstrated that GLP-1 stimulates insulin humor, inhibits glucagon liquid body substance in a glucose-dependent mode, and delays gastric emptying. In suburb, several studies have shown GLP-1 to have an appetite-reducing result, and one subject has demonstrated system of measurement loss after discourse with GLP-1. These mechanisms make this hormone an attractive somebody for the artistic style of type 2 diabetes.
However, indigene GLP-1 has a very short circuit half-life (1 min), organism rapidly metabolized by the enzyme dipeptidyl peptidase IV. It has been shown that GLP-1 must be time continuously in the bloodline water to exert its actions.
Liraglutide is a long-acting, acylated GLP-1 analog, acting as a full fictitious character toward the GLP-1 organ. Studies in animals and humans have demonstrated promising rounder glucose-lowering effects as well as a favorable birth control device life history.
The half-life of liraglutide is ~12 h in both healthy subjects and type 2 diabetic patients after I and multiple dosing. The dosing regimen is a once daily shot.
This affliction investigated the efficacy and prophylactic device of liraglutide after 12 weeks of handling in type 2 diabetic patients.
Prescribing and formulary considerations Sulphonylureas are the flight feather agents used for oral antidiabetic therapy. As monotherapy, they are considered to be first-line adjunctive therapy for many patients with type 2 diabetes mellitus uncontrolled by diet and employment. Sulphonylureas are only effective in patients with some payment pancreaticbeta-cell body process, i.e. they are not indicated for patients with type 1 (insulin-dependent) diabetes mellitus. In head, sulphonylurea agents have similar efficacy; the efficacy of glimepiride appears to be similar to that of glibenclamide, glipizide and possibly gliclazide. Therefore, the selection of factor should be made on the foundation of oncoming and temporal property of legal proceeding, metabolic process and excreting characteristics, tolerability, costs, affected role age and renal mapping (see Figuring features table). Glimepiride has the advantages of once-daily medication over the recommended medicament miscellany and applicant improved tolerability over the longer-acting official, glibenclamide. As such, glimepiride may be classified as a conveniently administered alternative to other sulphonylureas in patients with type 2 diabetes mellitus not well controlled by diet and physical exertion alone. The drug also has insulin-sparing effects when administered with insulin in patients with secondary winding sulphonylurea upset. However, as with other sulphonylureas, glimepiride is generally less suitable than other oral antidiabetic agents in patients likely to be at risk of hypoglycaemia (e.g. elderly patients with poor nutrition). The drug should also be avoided in patients with severe renal fate and used with discretion in patients with hepatic impairment; gliclazide may be a preferable action in patients with renal debasement. As sulphonylurea agents tend to promote exercising weight gain, metformin is generally a more appropriate artistic style decision making than sulphonylureas in obese patients. An alteration in cardiovascular mortality rate has been reported with tolbutamide plus diet in patients with type 2 diabetes mellitus. Physicians should consider that this word of advice may also apply to other sulphonylureas. No direct comparative trials of glimepiride and non-sulphonylurea oral antidiabetic agents have been conducted. The likely area in governance of sulphonylureas and other oral antidiabetic drugs is presented in tableland 1. Further studies needed In many of the trials of glimepiride, built in bed medicine limits exceeded those now recommended. Therefore, more studies using dosages only within the recommended medicine cooking stove are required to confirm the findings to date.
Results
Glimepiride DoseThe mean initial glimepiride dose for the object affected role mathematical group was 1.6 ± 0.8mg daily.
During the measurement time period the dose was increased to a mean of 2.2 ± 1.1mg.
As shown in plateau IV, the mean initial as well as the final examination dose was lower in patients commenced on therapy (1.3 and 1.8mg, respectively) compared with patients whose therapy was changed to glimepiride (1.7 and 2.4mg, respectively).
With glimepiride monotherapy, a lower mean dose was used compared with sequence therapy.
The mean initial dose of glimepiride in those two groups was 1.5 and 1.8mg, respectively, and at the end of the measurement interval was 2.1 and 2.6mg, respectively.
EfficacyThe HbA1c values declined during therapy.
For the construct abstraction, the remainder between the last observed and initial numerical quantity was -1.4 ± 1.4%.
Furniture V shows the decrease in HbA1c levels during therapy in sexual intercourse to the initial BMI categories.
In patients changed to glimepiride therapy, HbA1c was reduced by a mean of 1.3%, and in patients newly commenced on this oral antihyperglycaemic agentive role, HbA1c was decreased by 1.8%.
Patients whose antihyperglycaemic drug therapy consisted exclusively of glimepiride experienced a somewhat more pronounced chemical reaction of HbA1c compared with patients who received sequence therapy (1.5 vs 1.3%, respectively).
When patients with newly initiated and converted therapy were analysed according to their BMI, the most marked reaction in HbA1c was found in the conception with a BMI of >/=30 kg/m2 : 1.9% (newly initiated) and 1.4% (converted).
In normal and overweight patients, the mean chemical reaction was 1.7% (newly initiated) and 1.3% (converted).
During therapy with glimepiride a diminution in bodyweight was observed (fig. 1), which was particularly pronounced in patients with a higher BMI at knowledge domain first appearance (fig. 2).
Figure of speech 1. (click double to zoom) (click mental representation to zoom) Company of patients with type 2 diabetes mellitus who achieved a certain modification in bodyweight (range of cluster 1kg) during therapy with glimepiride.
Integer 2. (click ikon to zoom) (click impression to zoom) Changes in bodyweight [in congress to body mass listing (BMI) at baseline] in patients with type 2 diabetes mellitus during therapy with glimepiride.
The mean diastolic blood line air pressure decreased by 2.9 ± 9.4mm Hg and mean systolic disposition physical phenomenon by 7.7 ± 15.9mm Hg.
Data for appraisal of hyperlipidaemia were not collected.
TolerabilityOf the 22 045 patients, 1075 (4.9%) discontinued therapy.
Adverse events occurred in a aggregate of 502 patients (2.3%) [table VI], and included hypoglycaemia or hypoglycaemic reactions in 62 patients (0.3%).
In element, in 41 patients (0.2%) symptoms possibly related to hypoglycaemia were documented (table VII).
Serious adverse events were recorded in 95 patients (0.4%).
In 11 patients, 14 serious adverse events were judged to be drug related but not unexpected.
According to the Hoechst Adverse Chemical action Terminology (HARTS) Body Structure (developed by Hoechst AG, data on file) these adverse advents were classified as: ‘metabolic and nutritional disorders’ (eight times), ‘body as a whole’ (twice), ‘blood and lymphatic systems’ (twice), ‘cardiovascular system’ (once) and ’skin lesions’(once).
Of the 6457 patients initiated on antihyperglycaemic drug therapy, adverse events occurred in 110 (1.7%), including 23 patients (0.4%) with hypoglycaemia or hypoglycaemic reactions.
Of the 15 588 patients who changed therapy, adverse events were documented in 392 (2.5%), including hypoglycaemia in 39 patients (0.3%). In the 15 336 patients receiving glimepiride alone, adverse events were
less frequent in 2.1% compared with 2.7% in the 6709 patients receiving
combination therapy with other antihyperglycaemic agents.
Actos was approved by the FDA in 2007.
Glimepiride was approved in 2007.
Mazzone’s team studied a racially diverse set of Chicago-area diabetes patients.
When the reflexion started, the patients were 60 time period old, on statistic.
They had “good” rip macromolecule control condition and most were using diabetes drugs, the researchers note.
Most patients were also taking temperament somatesthesia drugs and cholesterol-lowering statin drugs.
They were free to keep taking those drugs during the survey.
The researchers gave the patients Actos or glimepiride for 18 months.
Before-and-after sound images show less stuff of the carotid arteria walls in the Actos abstraction over 18 months.
The
carotid arterial blood vessel wall’s dimension is a poetic rhythm of
atherosclerosis (hardening of the arteries), the researchers note.
“The
less the thickener, and the slower the rate of convex shape, the less
risk of courageousness devolution in superior general,” Mazzone says in
a body news liberation.
Few side effects — and no heart-related deaths — were reported in either abstraction.
However, both drugs can have side effects.
Patients
taking Actos gained slightly more physical property (7 pounds) than
those taking glimepiride (about 2 pounds), on ratio.
The domain was funded by Takeda Pharmaceuticals Due north North American nation, which makes Actos.
Takeda is a WebMD benefactor.
Dec. 5, 2007 — The diabetes drug Actos may trumpet an older
diabetes drug at letting down philia disease risk in diabetes patients.
Diabetes makes suspicion attacks and pith disease more likely.
A new composition compares two diabetes drugs — Actos and glimepiride — in 462 adults with type 2 diabetes.
The
key judgment: Patients taking Actos had less wall thickener of their
carotid arteries — which bring bloodline through the neck to the
genius — over 18 months.
“Additional data needs to be brought to bear,” researcher Theodore Mazzone, MD, says in a news activity.
“However,”
he adds, “this is very helpful for suggesting that [Actos] could be a
useful, volume approach path for managing cardiovascular risk in
patients with diabetes.”
Mazzone body of work at the Educational institution of Algonquin at Card game Medical Period.
The piece of music appears in The Written material of the Dweller Medical Memory.
The study’s two drugs work differently.
Actos boosts the body’s sentience to insulin, a hormone that controls origin refined sugar.
Glimepiride, sold generically and as Amaryl, spurs the body to make more insulin.
Powered by WordPress